Cannabis and cannabinoids in New Zealand

Global business and regulatory news covering the cannabis industry

24th October 2023

New Zealand reclassifies low-dose CBD medical products, effects yet to be seen

19th December 2022

Hong Kong to ban CBD in the new year, ending a once-burgeoning business

15th April 2021

Tilray expands its influence Down Under, moving on New Zealand medical market

More News analysis

Daily regulatory updates of legal changes in the cannabis sector, including monthly compilations

1st October 2024: New Zealand: The dried cannabis flower for preparation of tea for oral consumption ANTG Duke has been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
16th August 2024: New Zealand: The dried cannabis flower for preparation of tea for oral consumption Medleaf MAC-1 has been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
9th August 2024: New Zealand: The dried cannabis flower for preparation of tea for oral consumption Medleaf Runtz M has been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
30th July 2024: New Zealand: The dried cannabis flower for preparation of tea for oral consumption Medleaf Tropicana has been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
11th July 2024: New Zealand: The dried cannabis flower products Rua Puāwai THC26 and Rua Puāwai THC18 White Widow for use with a vaporiser have been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
8th July 2024: New Zealand: Last week, the Cabinet approved the Misuse of Drugs (Medical Cannabis) Amendment Regulations 2024. Among the changes, exports of cannabis-based ingredients (including CBD products as ingredients or finished products) and medical cannabis products destined for overseas markets, manufactured under Good Manufacturing Practice and accepted by the importing country will not need to be tested against the minimum quality standards. The amendments came into force on 5th July 2024.
11th June 2024: New Zealand: The dried cannabis flower product “KIKUYA Cove THC 190 mg/g and CBD ≤10 mg/g” for use via a vaporiser has been verified by the Medical Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
12th April 2024: New Zealand: ANTG Luna Oil THC 10 CBD 10 oral liquid has been verified by the Medical Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
5th April 2024: New Zealand: ANTG Rocky Oil THC 30 oral liquid and Tilray Whole Flower Dried Cannabis THC 25 (for inhalation via a vaporiser) have been verified by the Medical Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
3rd November 2023: New Zealand: Final election results released today (3rd November) show the centre-right National Party with a majority of seats (48 out of 122). National Party leader Christopher Luxon said during a press conference that his party was in talks with the right-wing ACT Party and New Zealand First to form a government. During his campaign, Luxon said that he was “comfortable with the current settings” when commenting on cannabis and rejected a bipartisan approach to decriminalisation.
2nd November 2023: New Zealand: Eqalis CBD30, Eqalis CBD120, Symetis T17 B52, Symetis T17 Gorilla and Cumulus T17 have been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
17th October 2023: New Zealand: The Medicines and Medical Devices Safety Authority (Medsafe) has reclassified CBD from a prescription-only medicine to a restricted (pharmacist-only) medicine. This will allow registered pharmacists to supply patients with approved low-dose CBD medicines without prescription. Currently, there are no low-dose CBD-containing medicines approved under the country’s laws.

Full-length in-depth reports with detailed data and analysis for individual markets around the world

6th September 2024

New Zealand: medical cannabis snapshot, September 2024

More Market reports

Regulatory reports

Comprehensive legal reports outlining how the sector is regulated, interpretation of the laws and relevant bodies

6th September 2024

New Zealand: medical cannabis snapshot, September 2024

5th May 2022

New Zealand: CBD and cannabis regulation, May 2022

4th March 2022

Medical and recreational cannabis – a global overview

More Regulatory reports

Up-to-date information and insights on brands, pricing and retail across selected markets

8th October 2024

Medical cannabis database

More Market data

Regulatory databases

Regularly updated global regulations currently in place, compiled into easy-to-read maps and tables

9th October 2024

Regulatory tracker: current global regulation of CBD, October

8th October 2024

Medical cannabis database

27th September 2024

Regulatory tracker: current global regulation of recreational cannabis

More Regulatory databases

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Corporate Email*

Name*

Name

This field is for validation purposes and should be left unchanged.